KAYLEE ANKROM: Open Payments
NPI 1104474741 · BOLIVAR, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$319 in 18 payments from 11 companies in 2025. Trend: 2023 $529 · 2024 $401 · 2025 $319
Food & beverage: $319
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 6 | $101 |
| Vanda Pharmaceuticals Inc. | 2 | $45 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $41 |
| Dexcom, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| GlaxoSmithKline, LLC. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Exact Sciences Corporation | 1 | $16 |
| AstraZeneca Pharmaceuticals LP | 1 | $15 |
| Merck Sharp & Dohme LLC | 1 | $15 |
Products named: MOUNJARO, FANAPT, CAPLYTA, Dexcom G6 Transmitter, Veozah, SHINGRIX, KISUNLA, REXULTI.
Industry payments across MO — which companies pay providers there.
